Wahl Bryan 4

What Happened
Bryan Wahl, General Counsel of Tarsus Pharmaceuticals (TARS), was granted derivative awards on 2026-03-05: 27,310 option-form shares and 17,161 restricted stock units (RSUs), for a total of 44,471 awards. Both grants show an acquisition price of $0.00 (award/compensation), so there was no cash purchase or sale and no immediate change in market ownership.

Key Details

• Transaction date: March 5, 2026; reported on Form 4 filed March 9, 2026 (4 days after the transaction). Filing appears to be late relative to the usual 2-business-day Form 4 deadline.
• Instrument & counts: 27,310 option-type derivative shares (footnote F1) and 17,161 RSUs (footnotes F2–F3); total 44,471 awards. Price per share: $0.00 (award).
• Vesting:
  • Options (F1): 25% vest on March 5, 2027, with additional monthly vesting thereafter per the footnote (monthly installments over the following period).
  • RSUs (F2–F3): each RSU converts to one share; RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029 and 2030.
• Shares owned after transaction: Not disclosed in this filing.
• Transaction code: A = Grant/Award. These are compensation awards, not open-market purchases or sales.

Context
These awards are standard equity compensation: RSUs convert to shares only when they vest, and the option awards require vesting (and likely later exercise) before becoming tradable shares. There was no immediate sale or cashless exercise reported. Awards do not, by themselves, indicate insider buying or selling intent—rather they reflect company compensation to the executive.